IMUGENE LIMITEDIMUGENE LIMITEDIMUGENE LIMITED

IMUGENE LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪364.43 M‬AUD
−0.021AUD
‪−149.68 M‬AUD
‪6.28 B‬
Beta (1Y)
0.69

About IMUGENE LIMITED


CEO
Leslie Chong
Headquarters
Sydney
Founded
1986
ISIN
AU000000IMU9
FIGI
BBG000BZ3TD8
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Analyze a symbol's price movements over past years with our seasonal tools, helping you spot repeating annual trends and better gauge potential market patterns.

Frequently Asked Questions


The current price of IMU is 0.048 AUD — it has decreased by −2.04% in the past 24 hours. Watch IMUGENE LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMUGENE LIMITED stocks are traded under the ticker IMU.
IMU stock has fallen by −4.00% compared to the previous week, the month change is a −9.43% fall, over the last year IMUGENE LIMITED has showed a 6.67% increase.
We've gathered analysts' opinions on IMUGENE LIMITED future price: according to them, IMU price has a max estimate of 0.42 AUD and a min estimate of 0.10 AUD. Watch IMU chart and read a more detailed IMUGENE LIMITED stock forecast: see what analysts think of IMUGENE LIMITED and suggest that you do with its stocks.
IMU reached its all-time high on Jun 30, 1994 with the price of 7.359 AUD, and its all-time low was 0.004 AUD and was reached on Jun 17, 2013. View more price dynamics on IMU chart.
See other stocks reaching their highest and lowest prices.
IMU stock is 2.08% volatile and has beta coefficient of 0.69. Track IMUGENE LIMITED stock price on the chart and check out the list of the most volatile stocks — is IMUGENE LIMITED there?
Today IMUGENE LIMITED has the market capitalization of ‪364.43 M‬, it has decreased by −2.00% over the last week.
Yes, you can track IMUGENE LIMITED financials in yearly and quarterly reports right on TradingView.
IMUGENE LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IMU earnings for the last half-year are −0.01 AUD per share, whereas the estimation was −0.01 AUD, resulting in a 0.00% surprise. The estimated earnings for the next half-year are −0.01 AUD per share. See more details about IMUGENE LIMITED earnings.
IMUGENE LIMITED revenue for the last half-year amounts to ‪−1.55 M‬ AUD, despite the estimated figure of 0.00 AUD. In the next half-year revenue is expected to reach ‪3.50 M‬ AUD.
IMU net income for the last half-year is ‪−80.97 M‬ AUD, while the previous report showed ‪−68.71 M‬ AUD of net income which accounts for −17.83% change. Track more IMUGENE LIMITED financial stats to get the full picture.
No, IMU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMUGENE LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMUGENE LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMUGENE LIMITED stock shows the sell signal. See more of IMUGENE LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.